Neumora Therapeutics Inc. Common Stock
NMRA | NASDAQ
$0.69
-$0.04 (-5.48%)
At close: Sep 21, 2026, 4:00 PM ET
$0.71
+$0.02 (+3.42%)
Pre-market:
Sep 22, 2026, 9:01 AM ET
TTM Period Ending | Q2 2026 Jun 29, 2026 | Q1 2026 Mar 30, 2026 | Q4 2025 Dec 30, 2025 | Q3 2025 Sep 29, 2025 | Q2 2025 Jun 29, 2025 | Q1 2025 Mar 30, 2025 | Q4 2024 Dec 30, 2024 | Q3 2024 Sep 29, 2024 | Q2 2024 Jun 29, 2024 | Q1 2024 Mar 30, 2024 | Q4 2023 Dec 30, 2023 | Q3 2023 Sep 29, 2023 | Q2 2023 Jun 29, 2023 | Q1 2023 Mar 30, 2023 | Q4 2022 Dec 30, 2022 | Q3 2022 Sep 29, 2022 | Q2 2022 Jun 29, 2022 | Q1 2022 Mar 30, 2022 | Q4 2021 Dec 30, 2021 | Q3 2021 Sep 29, 2021 | Q2 2021 Jun 29, 2021 | Q1 2021 Mar 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 5.01M | 5.01M | 5M | 5M | n/a | n/a | n/a | 166K | 166K | 166K | 166K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | -5.01M | -5.01M | -5M | -5M | n/a | n/a | n/a | -166K | -166K | -166K | -166K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -211.23M | -223.08M | -241.16M | -245.6M | -264.54M | -274.33M | -263.46M | -250.64M | -230.86M | -209.1M | -188.19M | -168.81M | -142.55M | -131.8M | -135.87M | -131.7M | -279.23M | -265.11M | -237.32M | -230.3M | -52.17M | -34.97M |
Interest Income | 5.19M | 6.07M | 7.91M | 10.66M | 13.19M | 16.64M | 19.93M | 21.49M | 21.12M | 19.41M | 16.61M | 13.25M | 10.82M | 8.04M | 4.56M | 2.28M | 870K | 86K | n/a | n/a | n/a | n/a |
Pretax Income | -212.72M | -222.34M | -236.8M | -236.17M | -251.91M | -257.78M | -243.61M | -293.25M | -273.79M | -253.75M | -235.66M | -155.34M | -131.66M | -123.49M | -130.9M | -129.73M | -278.41M | -265.05M | -237.31M | -230.34M | -52.31M | -35.3M |
Net Income | -212.75M | -222.39M | -236.93M | -236.3M | -252.09M | -258.06M | -243.79M | -293.7M | -274.18M | -254.02M | -235.93M | -155.34M | -131.66M | -123.49M | -130.9M | -129.73M | -278.41M | -265.05M | -237.31M | -230.34M | -52.31M | -35.3M |
Selling & General & Admin | 53.16M | 55.57M | 60.09M | 63.29M | 67.13M | 67.01M | 62.54M | 56.6M | 55.84M | 49.94M | 45.31M | 41.43M | 34.22M | 32.72M | 31.12M | 31.56M | 30.17M | 28.69M | 24.55M | 21.2M | 14.54M | 8.24M |
Research & Development | 153.07M | 162.51M | 176.07M | 177.31M | 197.42M | 207.32M | 200.93M | 193.88M | 174.85M | 158.99M | 142.72M | 127.38M | 108.33M | 99.09M | 104.75M | 100.14M | 249.06M | 236.42M | 212.78M | 209.1M | 37.63M | 26.74M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 206.23M | 218.08M | 236.16M | 240.6M | 264.54M | 274.33M | 263.46M | 250.48M | 230.69M | 208.93M | 188.03M | 168.81M | 142.55M | 131.8M | 135.87M | 131.7M | 279.23M | 265.11M | 237.32M | 230.3M | 52.17M | 34.97M |
Interest Expense | 6.46M | 4.64M | 2.78M | 747K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 211.23M | 223.08M | 241.16M | 245.6M | 264.54M | 274.33M | 263.46M | 250.64M | 230.86M | 209.1M | 188.19M | 168.81M | 142.55M | 131.8M | 135.87M | 131.7M | 279.23M | 265.11M | 237.32M | 230.3M | 52.17M | 34.97M |
Income Tax Expense | 30K | 55K | 130K | 130K | 183K | 283K | 178K | 446K | 393K | 268K | 268K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 185.16M | 179.87M | 163.39M | 161.84M | 161.69M | 161.45M | 160.98M | 159.58M | 158.98M | 157.94M | 158.83M | 155.39M | 151.95M | 151.95M | 151.95M | 151.95M | 151.95M | 151.95M | 151.95M | 151.95M | 151.95M | 151.95M |
Shares Outstanding (Diluted) | 185.16M | 179.87M | 163.39M | 161.84M | 161.69M | 161.45M | 160.98M | 159.58M | 158.98M | 157.94M | 158.83M | 155.39M | 151.95M | 151.95M | 151.95M | 151.95M | 151.95M | 151.95M | 151.95M | 151.95M | 151.95M | 151.95M |
EPS (Basic) | -1.23 | -1.33 | -1.45 | -1.47 | -1.57 | -1.61 | -1.53 | -1.84 | -1.73 | -1.61 | -1.50 | -1.01 | -0.86 | -0.81 | -0.86 | -0.85 | -1.83 | -1.74 | -1.56 | -1.51 | -0.34 | -0.23 |
EPS (Diluted) | -1.23 | -1.33 | -1.45 | -1.47 | -1.57 | -1.61 | -1.53 | -1.84 | -1.73 | -1.61 | -1.50 | -1.01 | -0.86 | -0.81 | -0.86 | -0.85 | -1.83 | -1.74 | -1.56 | -1.51 | -0.34 | -0.23 |
EBITDA | -207.14M | -217.64M | -233.81M | -235.06M | -251.42M | -257.15M | -242.98M | -292.61M | -273.13M | -253.09M | -234.99M | -154.69M | -131.04M | -122.88M | -130.31M | -129.15M | -277.83M | -264.5M | -236.92M | -229.54M | -51.66M | -34.78M |
EBIT | -207.18M | -217.7M | -234.02M | -235.42M | -251.91M | -257.78M | -243.61M | -293.25M | -273.79M | -253.75M | -235.66M | -155.34M | -131.66M | -123.49M | -130.9M | -129.73M | -278.41M | -265.05M | -237.45M | -230.01M | -51.98M | -34.97M |
Depreciation & Amortization | 40K | 59K | 208K | 356K | 489K | 630K | 631K | 640K | 657K | 668K | 668K | 649K | 622K | 605K | 594K | 578K | 582K | 553K | 538K | 470K | 320K | 195K |
Add to Watchlist
Select watchlists to add or remove NMRA